



30 December 2020

Corey Lian  
Australian Securities Exchange  
Exchange Centre  
20 Bridge Street  
Sydney, NSW 2000

Dear Corey

### APPENDIX 3Y

Please find attached a copy of an Appendix 3Y relating to the sale of 100,000 shares held in a superannuation fund beneficially owned by Medlab's Chairman, Mr Michael Hall.

In accordance with Listing Rule 18.7, I can advise that:

1. The trade was completed on 14 December 2020 and therefore the lodgement of the Appendix 3Y is late. Mr Hall inadvertently forgot to advise the Company and apologises for the oversight.
2. The Company has policies in place where directors are required to notify the Board and Company Secretary of any trades completed in order for the Company Secretary to advise the ASX.
3. The Board is confident in the current arrangements to ensure compliance with Listing Rule 3.19B as illustrated by the fact that this was an isolated event.

For and behalf of the Board.

Alan Dworkin  
Company Secretary

#### About Medlab – [www.medlab.co](http://www.medlab.co)

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, NanoCelle™ is being applied to its medicines, nutritional products and off-patent drugs like statins, Medlab has a growing patent portfolio.

For further information contact:

Dr Sean Hall, CEO Medlab Clinical  
T: + 61 2 8203 9520 – [sean\\_hall@medlab.co](mailto:sean_hall@medlab.co)

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Medlab Clinical Limited</b>
<b>ABN</b>	<b>51 169 149 071</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Michael Jack Hall
<b>Date of last notice</b>	12 November 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	a) FIT Investments Pty Ltd ATF Hallab Investments Trust b) Michael Hall & Elizabeth Jones ATF Hall Jones Superannuation Fund
<b>Date of change</b>	14 December 2020
<b>No. of securities held prior to change</b>	a) 12,334,445 Ordinary shares b) 3,572,938 Ordinary Shares b) 2,000,000 unlisted \$0.20 options expiring 31 October 2022
<b>Class</b>	Unlisted Options
<b>Number acquired</b>	Nil
<b>Number disposed</b>	b) 100,000
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$27,500.00

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	c) 12,334,445 Ordinary shares d) 3,472,938 Ordinary Shares c) 2,000,000 unlisted \$0.20 options expiring 31 October 2022
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market trade

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

## Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	Yes
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Yes
<b>If prior written clearance was provided, on what date was this provided?</b>	16 November 2020

+ See chapter 19 for defined terms.